There is a significant link between pruritus and patient/caregiver quality of life (QoL) in patients with atopic dermatitis (AD) treated with crisaborole, a new study found. Patients aged ≥2 years were randomly assigned to received crisaborole or vehicle twice daily for 28 days. QoL was measured at baseline and day 29 using the Dermatology Life Quality Index (DLQI; patients aged ≥16 years), the Children’s Dermatology Life Quality Index (CDLQU; patients aged 2-15 years), and the Dermatitis Family Impact (DFI; caregivers of patients aged 2-17 years). Pruritus was measured using the Severity of Pruritus Scale (SPS) and captured morning and evening via electronic diary. Researchers found:

• 1,522 patients received crisaborole or vehicle.
• A linearity assumption for the relationships between SPS and DLQI (n=294), CDLQI (n=1,200), and DFI (n=1,293) was appropriate.
• The pattern of relationships between SPS, CDLQI, and DFI were similar.